Skip to Content
Merck
CN
  • Identification of CB₂ receptors in human nigral neurons that degenerate in Parkinson's disease.

Identification of CB₂ receptors in human nigral neurons that degenerate in Parkinson's disease.

Neuroscience letters (2014-12-08)
María Concepción García, Valentina Cinquina, Cristina Palomo-Garo, Alberto Rábano, Javier Fernández-Ruiz
ABSTRACT

It is well-demonstrated that cannabinoid CB2 receptors located in glial cells are up-regulated in neurodegenerative disorders serving as a target to control glial influences to neurons. Recent evidence indicates that CB2 receptors may be also located in certain neuronal subpopulations and serve as a marker of neuronal losses. We investigated this possibility in the post-mortem substantia nigra of Parkinson's disease (PD) patients and controls. Immunostaining for the CB2 receptor was found in tyrosine hydroxylase-positive neurons in the substantia nigra, a fact confirmed with double-staining analyses. The signal was found in controls but also in PD patients, in which CB2 receptor labelling was significantly lower, in parallel to the losses of these neurons experienced in the disease. These data show for the first time that CB2 receptors are located in tyrosine hydroxylase-containing neurons in the substantia nigra at levels significantly lower in PD patients compared to controls.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
DL-Tyrosine, 99%
Tyrosine, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
3,3′-Diaminobenzidine, 97%
Sigma-Aldrich
3,3′-Diaminobenzidine, 97% (HPLC)